Cubist Pharmaceuticals Names Thomas Slater as Vice President, Commercial DevelopmentCubist Pharmaceuticals, Inc.CUBIST PHARMACEUTICALS NAMES THOMAS SLATER AS VICE PRESIDENT, COMMERCIAL DEVELOPMENT Cambridge, MA, May 25, 1999 - Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today announced the appointment of Thomas Slater as Vice President, Commercial Development.Mr. Slater will be responsible for the marketing, commercialization and partnering strategies of daptomycin and follow-on drug candidates.In this newly created position, Mr. Slater will report to Scott Rocklage, Ph.D. President and CEO of Cubist.Mr. Slater brings to Cubist over twenty years of pharmaceutical and biotech sales, marketing and commercial development experience from Genzyme and Hoffman LaRoche.He most recently served as Vice President, Biomaterials Business at Genzyme and was responsible for all commercialization and strategic activities of the Biomaterials Business.Mr. Slater's appointment is another key addition to help Cubist advance daptomycin to the market as quickly as possible.I am very pleased we have hired such an enthusiastic and talented individual as Tom to manage and refine our plans."Daptomycin is a novel antibiotic currently in Phase III clinical trials to evaluate safety and efficacy in treating complicated skin and soft tissue infections and in a Phase II trial to treat bloodstream infections not associated with endocarditis.Interim results from the Phase II open label bacteremia trial are scheduled to be reviewed mid-year.Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel antimicrobial drugs to combat serious and life threatening bacteria and fungi infections.Cubist is engaged in strategic partnerships with Novartis Pharma AG, Merck & Co., Inc. and Bristol-Myers Squibb for the discovery and development of novel antiinfective products, and has formed biotechnology alliances with ArQule, Inc., Helios, Inc., and Neurogen Corporation.

Thomas J. Slater, Vice President, Commercial Development Thomas J. Slater, Vice President, Commercial Development Thomas J. Slater has served as our Vice President, Commercial Development & International since May 1999. In 2005 Mr. Slater added responsibility for managing international sales and alliance management through a network of international partners. From July 1998 to April 1999, he served as Senior Vice President of Business Development for Newport Strategies, a pharmaceutical consulting company. From January 1996 to July 1998, he served as Vice President, Pharmaceuticals & Fine Chemicals for Genzyme Corporation, where he was responsible for building a $50 million business in actives drug substances, intermediates, phospholipids and hyaluronic acid products. From 1988 to January 1996, Mr. Slater served in various sales and marketing positions for Genzyme Corporation. Prior to 1988, Mr. Slater served in marketing and sales positions for the pharmaceutical companies Hoffmann-LaRoche and Upjohn. Mr. Slater received his B.S. degree in Biology from Upsala College.

Thomas J. Slater Thomas J. Slater Vice President, Commercial Development > More Information